SynthesisPloS one2014
Risk of multiple myeloma in rheumatoid arthritis: a meta-analysis of case-control and cohort studies.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Rheumatoid arthritis and risk of site-specific cancers: Mendelian randomization study in European and East Asian populations.Arthritis research & therapy · 2022Pooled it
- The risk of leukemia in patients with rheumatoid arthritis: a systematic review and meta-analysis.Clinical rheumatology · 2021Pooled it
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Rheumatoid arthritis and the risk of hematologic malignancies: a nationwide cohort study.Leukemia · 2025Article
- Use of disease modifying anti-rheumatic drugs and risk of multiple myeloma in US Veterans with rheumatoid arthritis.BMC rheumatology · 2025Article
- Association of ANA and SSA autoantibodies with progression-free survival in multiple myeloma: a retrospective cohort study.Frontiers in oncology · 2025Article
- Osteoarthritis as a Systemic Disease Promoted Prostate Cancer In Vivo and In Vitro.International journal of molecular sciences · 2024Article
- The casual relationship between autoimmune diseases and multiple myeloma: a Mendelian randomization study.Clinical and experimental medicine · 2024Article
- Rheumatoid arthritis and cancer risk in the Million Women Study.International journal of epidemiology · 2024Article
- Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study.The Lancet regional health. Europe · 2023Article
- Migraine and risk of rheumatoid arthritis: A systematic review and meta-analysis of observational studies.Heliyon · 2023Article
- Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα.Blood advances · 2021Article
- Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.Blood advances · 2021Article
- Appraisal of the Antiarthritic Potential of Prazosin via Inhibition of Proinflammatory Cytokine TNF-α: A Key Player in Rheumatoid Arthritis.ACS omega · 2021Article
- Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma.International journal of cancer · 2020Article
- The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network.Cancer epidemiology · 2019Article
- Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Rheumatology and therapy · 2017Review
- Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.BBA clinical · 2016Review
- AL Amyloidosis in a Patient with Long-Standing Rheumatoid Arthritis: Is there a Link with Autoimmune Disease and Monoclonal Gammopathy of Renal Significance?Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesmultiple myeloma is a malignant neoplasm of plasma cells mainly affecting elderly patients. Despite the wealth of information available on therapeutic strategies, the etiology and pathogenesis of myeloma remain unclear. In the current study, a meta-analysis was conducted to assess the possible association between rheumatoid arthritis and myeloma.
methodsa literature search was conducted with PubMed, EMBASE and Web of Science for relevant studies published by December 25, 2013. Additionally, we searched annual meeting abstracts of the American Society of Hematology from 2004 to 2013. Only original studies that investigated the association between rheumatoid arthritis and myeloma were included. In total, 8 case-control and 10 cohort studies were identified for analysis.
resultsthe meta-estimate of the association between rheumatoid arthritis and myeloma was 1.14 (95% CI, 0.97-1.33) overall, with significant heterogeneity among studies. The relationship between myeloma and other autoimmune diseases was additionally examined from available data. Our results showed that myeloma risk is increased 1.31 to 1.65-fold in pernicious anemia and 1.36 to 2.30-fold in ankylosing spondylitis patients.
conclusionRheumatoid arthritis does not appear to alter the risk of myeloma, while between-study heterogeneity analyses suggest caution in the interpretation of results. Pernicious anemia and ankylosing spondylitis may be potential risk factors for myeloma development. Future large-scale epidemiological studies with reliable exposure biomarkers are necessary to establish the possible contribution of autoimmune disorders to multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.